Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Published:2018-10 Issue:10 Volume:13 Page:1539-1548
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Wu Yi-Long,Lu Shun,Lu You,Zhou Jianying,Shi Yuan-kai,Sriuranpong Virote,Ho James C.M.,Ong Choo Khoon,Tsai Chun-Ming,Chung Chin-Hee,Wilner Keith D.,Tang Yiyun,Masters Elizabeth T.,Selaru Paulina,Mok Tony S.

Funder

Pfizer Inc.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007

3. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression;Zhang;Mol Cancer,2010

4. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases;Sun;J Clin Oncol,2010

5. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma;Christensen;Mol Cancer Ther,2007

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer;Cancers;2024-06-12

2. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23

3. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review;Advances in Therapy;2024-03-21

4. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study;Cancer Communications;2024-02-29

5. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis;BMC Cancer;2024-02-08